ARTICLE | Company News
XTL hepatitis C deal with Dong-Wha
July 18, 2001 7:00 AM UTC
XTL Biopharmaceuticals (LSE:XTL) will evaluate the efficacy of small molecule compounds for the treatment of hepatitis C from Dong-Wha Industrial (Seoul, Korea). The small molecules, already screened ...